Capricor Therapeutics Investor Deadline Looms for Class Action Suit
Purchasers of Capricor Therapeutics securities with substantial losses have a Monday deadline to lead a class action lawsuit concerning the company's financial reporting.
Purchasers or acquirers of Capricor Therapeutics, Inc. (NASDAQ: CAPR) securities between December 17, 2025, and July 26, 2026, have until Monday, September 23, 2026, to file as lead plaintiff in a class action lawsuit. The suit alleges that the company made materially misleading or false statements during the specified class period.
The lawsuit claims that Capricor Therapeutics issued statements that were likely false or misleading and omitted material information. Specifically, the complaint suggests that investors were not adequately informed about potential issues concerning the company's Rex gene therapy product and its clinical trials.
These alleged issues appear to relate to the company's purported inability to provide data demonstrating the product's efficacy and safety. While the exact nature of the allegations is not fully detailed, the legal action implies that investors suffered significant financial losses as a result.
Capricor Therapeutics is a biotechnology company focused on developing novel therapeutic approaches. The company has previously reported progress on its Rex gene therapy for treating certain cardiac conditions. The ongoing litigation could have a material impact on the company's future operations and its ability to advance its research and development pipeline.